Skip to content

Abbott ABT Free cash flow

Free cash flow at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$546M
Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Haemonetics logo
HaemoneticsHAE
$53.28M-47.2%
Artivion logo
ArtivionAORT
-$6.85M+66.7%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$24.67M+26.5%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$11.2B+7.8%
Gross profit$6.3B+6.5%
Operating income$1.3B-20.6%
Net income$1.1B-18.7%
EPS (diluted)$0.61-19.7%

Balance sheet

See full
Cash & equivalents$6.8B+4.1%
Total debt$34.0B+157%
Total equity$52.1B+6.7%
Total assets$110.43B+35.6%

Cash flow

See full
Operating cash flow$1.3B-7.2%
CapEx$399.0M-17.6%

Valuation

See full
Market cap$162.41B-29.8%
Enterprise value$189.65B-20.3%
P/E25.9×+8.7×
P/S3.6×-1.9×

Profitability

See full
Gross margin56.3%+0.4pp
Operating margin17.1%+0.2pp
Net margin13.9%-18.0pp
FCF margin16.3%+0.6pp

Returns & leverage

See full
Return on equity12.4%-18.4pp
Debt / equity0.7×+0.4×
Current ratio1.4×-0.4×

Where this comes from

Calculated from Abbott’s reported figures.

The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Abbott's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Abbott's free cash flow?
Abbott (ABT) reported free cash flow of $916M in Q1 2026.
How has Abbott's free cash flow changed year-over-year?
Abbott's free cash flow decreased by 1.8% year-over-year, from $933M to $916M.
What is the long-term trend for Abbott's free cash flow?
Over 4 years (2021 to 2025), Abbott's free cash flow has grown at a -3.8% compound annual growth rate (CAGR), from $8.65B to $7.4B.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.